Background: Invasive cervical carcinoma (ICC) accounts for 23% of all cancer-related deaths in Zimbabwean women. Trials for a national program of genotype-specific human papillomavirus (HPV) vaccines are underway to prevent cervical carcinoma, but the distribution of HPV types among women with ICC according to HIV status is unknown.
BACKGROUND
Invasive cervical carcinoma (ICC) is the fourth most common cancer globally. The highest incidence and mortality are found in low-to-middle income countries that account for 85% of the disease burden worldwide. In Zimbabwe, 1 ICC is the leading cause of cancer and cancer-related deaths in women; the crude incidence is 34.5 per 100,000 women per year, which results in 2270 new cases and 1451 deaths annually. 2 Cervical cancer and its precursor lesions are caused by the human papillomavirus (HPV), a sexually transmitted virus that infects women mostly during their reproductive years. 3 Approximately 90% of infections are cleared or controlled by the immune system within 2 years without causing clinical disease. The remaining 10% persist as viral wart infection, but some progress to preinvasive carcinoma and a small percentage ultimately to invasive carcinoma. 4 Cell transformation occurs through the actions of viral oncoproteins E6 and E7, which act in concert with cocarcinogens, cervical infections, and possibly a compromised immune system resulting in progressive dysplasia to invasive carcinoma. 5 Sub-Saharan Africa is decades into the HIV-pandemic. 6 The HIV prevalence rate in Zimbabwe stands at 16 .7% in adults (15-49 years) 3 with a prevalence of 4.2% in women aged 15-24 years (UNAIDS). Although the CDC declared cervical cancer to be an AIDS-defining illness in 1993, 7 the exact role played by HIV in the pathogenesis of ICC remains poorly understood. Studies on the effects of concomitant HIV and HPV infection are scarce, but most indicate that the vast majority of HIV-positive women are coinfected with HPV; ICC in HIV-positive women shows up to a 22-fold increase in incidence 8 and presents 10-15 years earlier. 9 In addition, some studies have reported that HIV-positive women harbor more HPV genotypes and have a larger number of multiple infections than their HIV-negative counterparts. 10 Certain high-risk (HR)-HPV types, ie, those most likely to progress to ICC, notably HPV 16 and 18, have been detected in more than 70% of ICC worldwide. 11 Variations in the prevalence of specific HPV genotypes have been reported from various world regions including sub-Saharan Africa. Some of the earliest international studies suggested that there may be HPV type-specific differences according to host immune status. 12 It is postulated that HPV-16, in particular, may account for the most cases of cervical cancer because of its innate ability to avoid immune surveillance. This may, in part, explain the differences seen in distribution of various genotypes, and more significantly, it may have implications on the currently available vaccines on the immunosuppression. In an earlier study from Zimbabwe, 13 97% of the women with ICC also had HPV infection, of which types 16 (61%), 33(39%), 18 (18%), and 31(4%) were the most prevalent genotypes obtained from the cervical scrapings. The study, however, did not take into consideration the patients' HIV status. A recent meta-analysis of studies from the sub-Saharan region confirmed that HPV 16 and HPV 18 are the most predominant types and account for a similar proportion of ICC irrespective on HIV status, although HPV 16 was slightly underrepresented compared with HPV 18 proportions in HIV-positive patients with ICC. 14 Currently, genotype-specific vaccines are being rolled out in many countries, including Zimbabwe, where a Gavifunded pilot project aimed at vaccinating girls aged 9-13 years is underway in Marondera and Beitbridge towns. 15 This study determined the prevalence of HPV genotypes associated with ICC in both HIV-positive and HIV-negative women in Zimbabwe. These data will allow policymakers to assess the potential impact of the vaccination program on the prevalence of ICC, particularly in a setting of high HIV prevalence. This knowledge is crucial, given the projected increase in the incidence and mortality from cervical cancer in sub-Saharan Africa over the next 20 years. 16 
MATERIALS AND METHODS

Study Participants
One hundred ninety-eight women, aged 18 years or older presenting with signs and symptoms suggestive of ICC were enrolled into the cross-sectional study between June and December 2014. Participants were referred from primary health care centers to the Gynecology Out Patient Departments of 4 major urban hospitals in Zimbabwe (2 in Harare and 2 in Bulawayo). Senior nursing staff received training on the recruitment of participants. Participants provided signed informed consent for an HIV test, CD4 count, and 2 cervical biopsies; the first was obtained for histological confirmation of cervical carcinoma and was placed immediately into 10% buffered formalin and sent to a consultant pathologist for routine histological assessment. The second, taken for HPV genotyping, was obtained from an area adjacent to the first. It was transported in normal saline and stored in an ultra-freeze at 281°C within 2-3 hours after biopsy. Histological assessment and storage facilities were available in both Harare and Bulawayo.
All the participants received pre-and post-HIV test counseling. On being informed of their HIV and biopsy results, participants were offered appropriate counseling and treatment options per standard of care.
Ethical Approval
Permission to conduct the study was granted by the clinical directors at all study sites (Parirenyatwa, Harare Central, United Bulawayo, and Mpilo Hospitals). 
Demographic, Medical, Sexual, and Reproductive History
Participants completed an interviewer-administered questionnaire where demographic, medical, sexual, and reproductive history data were collected.
HIV Serology and CD4 Count
HIV and CD4 testing were performed in the Department of Immunology, University of Zimbabwe. Rapid serum HIV antibody testing was performed using Alere Determine HIV Ag/Ab Combo kit Abbott acquired the alere in 2017 (Abbott, Chicago, IL). All positive cases were confirmed using First Response HIV1/HIV2 test kit (WB Premier Medical Corporation, Darman, India). A CD4 count was performed on all cases that tested positive for HIV with both kits.
Histology
One hundred ninety-eight women were recruited into the study. Hematoxylin and eosin-stained recut slides of the original cervical biopsies were obtained, and the initial histological diagnosis was reassessed. Ninety-one participants were excluded either because of normal histology, suboptimal tissue for diagnosis, incomplete patient data, in situ squamous lesions, or because of poor DNA quality (2 cases had negative human ß-globin). The final study sample meeting the inclusion criteria comprised 107 cases. Tumors were classified according to the World Health Organization's criteria (WHO Classification of Tumors of Female Reproductive Organs, 2014).
DNA Extraction and HPV Genotyping
DNA was extracted from the stored frozen biopsies using QIAGEN DNeasy Blood and Tissue kit (QIAGEN Incorporated, Valencia, CA) according to the manufacturer's instructions. The extracted DNA was first subjected to conventional polymerase chain reaction for human b-globin gene amplification as an internal control. Samples that were positive for human ß-globin gene were subjected to conventional polymerase chain reaction for HPV DNA viral amplification using MY09/MY11 primers (Eurofins, Hamburg, Germany). Two samples negative for ß-globin were among cases excluded from the study.
Genotyping was performed using dot-blot hybridization. Biotin-labeled probes for specific genotypes were mixed with the amplicon together with streptavidin-horseradish peroxidase. The presence of streptavidin-horseradish peroxidase was detected using the enhanced chemiluminescence method. The maximum light emission at a wavelength of 428 nm was detected by exposing the reaction to a negative film. Short exposure to blue light on an X-ray film allowed for the detection of specific reaction(s) denoting wells in which hybridization would have occurred. The selected probes were able to identify 14 HR-HPV genotypes (16, 18, 
Statistical Analysis
Baseline description of study participants was presented using percentages for categorical variables such as sex, and mean (SD) for continuous variables such as age, or median and range were the variable that was not normally distributed.
Prevalence and distribution of HPV genotypes were presented as percentages and histograms. The Mann-Whitney and x 2 tests were used to test for probability. Multiple infections were determined with an HPV multiple infection being described as infection with 2 or more HPV types. Level of significance was set at P = 0.05. All analyzes were conducted using Statistica version 12 (Tulsa, OK).
RESULTS
Histology
Histological analysis revealed that 90.6% (97/107) of the participants had squamous cell carcinoma, 5.6% (6/107) had adenocarcinoma, 1.9% (2/107) showed neuroendocrine differentiation, and the remaining 1.9% (2/107) were considered too necrotic to properly classify. Six participants showed squamous cell carcinoma together with the coincidental presence of Schistosoma ova. Table 1 shows HPV distribution by tumor subtype. Of the 6 cases showing adenocarcinoma, 4 were positive for HPV 18.
Age and HIV Status
The study sample consisted of 107 participants with histologically proven ICC. 
HPV Genotypes
The HPV prevalence was 94.4% (101/107), ranging from 1 to 5 genotypes per participant. It increased slightly from 93% (50/54) among HIV-negative cases to 96% (51/53) (Table 2) . However, only the prevalence of HPV 18 differed significantly between HIV-positive participants (43.4%) and HIV-negative patients (24.1%) (P = 0.03). Thirty-two percent (34/107) of participants had infection with HPV 16 as a single infection.
Fifty-one percent (55/107) of participants showed infection with multiple HR-HPV genotypes. This distributed as over half, 54.5% (30/55), for HIV-positive participants and 45.5% (25/55) for HIV-negative participants, but this difference was not statistically significant.
Participants on HAART had a higher prevalence of multiple infections than those not on HAART (28/36 vs 9/36).
Twenty-six percent (14/53) of HIV-positive participants had a CD4 count ,250 cells/mm 3 . There was no association between low CD4 count (,250 cells/mm 3 ) and increased prevalence of HR-HPV genotypes (P = 0.904). The distribution of the rest of the genotypes by HIV status is shown in Table 2 .
DISCUSSION
ICC accounts for 23% of all cancer-related deaths in Zimbabwean women and is second only to Kaposi sarcoma for overall cancer-related mortality in both sexes. 2 HPV infection is well established as the primary cause of ICC, and there is growing evidence of HPV being an important factor in other anogenital cancers such as anus, vulva, vagina, and penis. 8 What is less well established is the possible role of concomitant HIV infection, especially on the prevalence and genotypes of HPV. Zimbabwe has about 1.4 million people living with HIV/AIDS, 56% of these are women aged 15 years and older. 6 Prevalence rates of HPV infection in HIVpositive women in the age group 15-44 years exceed 90% with the most frequent oncogenic HR types being HPV 16 and 18. 3 Using MY09/11 primers, the current study assessed the prevalence of HPV genotypes and the effect of concomitant HIV infection on the distribution of HPV genotypes in women with histologically proven ICC.
Almost half (49.5%) of the study participants of women with ICC in Zimbabwe were HIV-positive. ICC was diagnosed in much younger women (on average 16 years earlier) among HIV-positive participants. Further studies taking into account the effect of the prevailing regional population structure, the stage at diagnosis and the period of both HIV and HPV infection are, however, required to ascertain the effect of HIV on rate of disease progression.
The overall HPV prevalence of 94% was in keeping with rates found elsewhere in literature. 11,17 HPV 16 and 18 remained the commonest HPV genotypes isolated in patients with ICC regardless of HIV status, being isolated in 83% of cases. The combined prevalence rates of HPV 16 and 18 were comparable in both HIV-positive (79%) and HIV-negative participants (87%). The spectrum of HPV genotypes seen in participants with ICC differed among HIV-positive and HIVnegative women. HIV-positive participants showed a slight reduction in cases infected with HPV 16, an almost doubling of HPV 18 and HPV 56 and quadrupling of HPV 58-positive cases. However, only the difference in the prevalence of HPV 18 by HIV status was found to be statistically significant. Similar findings were also reported in other studies 16, 18 including a recent meta-analysis by Clifford et al. 14 HPV genotypes ranged from 1 to 5 genotypes per participant with 51% of the participants showing the presence of multiple (2 or more) HR-HPV infections. Unlike in previous reports, 19, 20 we found no significant difference in the prevalence of multiple genotypes by HIV status. Although this could be attributed to our small sample size, recent studies have also shown that advances in technology and improved DNA extraction protocols have resulted in increased detection of HPV genotypes, 21 and therefore the unmasking of the role played by previously underestimated genotypes. We used fresh-frozen cervical tissue as our DNA source because some studies have proven this offers an improved DNA yield, which may also explain our higher HPV prevalence compared with, for instance, formalin-fixed paraffin-embedded tissue. 22 The increased rate of multiple genotypes was also associated with a decrease in the cases attributed to HPV 16 alone (32%) when compared with previous studies. The presence of a high proportion of concomitant in situ/CIN3 lesions within a biopsy, as seen in cases of early/microinvasive ICC, is also associated with detection of a wider variety of HPV genotypes, regardless of HIV status. 23, 24 In this study, emphasis was only placed on the presence or absence of invasive malignancy. Further studies using laser capture microscopy on H&E slides can be used to assess the presence of HR-HPV genotypes in cases with a microinvasive component and a large background CIN3 component. There was no association between the prevalence of multiple genotypes with any particular histological type. Although we only had 6 cases of adenocarcinoma, 4 of them were positive for HPV 18, prevalence of 66.7%, in keeping with this association seen in other studies. 18, 25 Participants on HAART had a higher incidence of multiple infections than those not on ARVs. HAART increases the life expectancy of women living with HIV and AIDS and therefore not only allows for increased potential exposure time to HR-HPV but also permits for accumulation of cellular genetic changes that ultimately lead to cervical cancer. 16 Although some studies have shown HAART to promote clearance of HR-HPV, its effect on the incidence and progression of high-grade cytological squamous intraepithelial lesions remains controversial. 26 The introduction of HAART more than 10 years ago in Zimbabwe has not been matched with a decline in the incidence of ICC. 1, 27 This may be due to lack of access to prevention and appropriate management services-only 30% of women in this study had ever received a Pap smear-incorrect and inconsistent use of HAART, and possibly due to differences in the molecular pathogenesis of ICC in HIV-positive and HIV-negative individuals. 28 The median CD4 count among HIV-positive participants was 337 cells/mm 3 (IQR = 232-486), and we found no association between low CD4 count (less than 250 cells/mm 3 ) and increased prevalence of HR-HPV genotypes.
Two vaccines, Cervarix, a bivalent vaccine offering protection against HPV 16 and HPV 18 and a quadrivalent vaccine, Gardasil, offering additional protection against HPV 6 and HPV 11, both nononcogenic types are available in most countries. The US Food and Drug Administration has approved Gardasil 9, a nonavalent vaccine that protects against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58, but it is yet to be widely distributed in sub-Saharan Africa. It has been calculated that a vaccine against the 7 most common HPV genotypes would prevent 87% of cases of ICC worldwide, whereas one effective against types 16 and 18 only would prevent 71% of cases. 29 The vaccines directed against HPV 16 and 18 have the potential to reduce up to 83% of cancer occurring in our population according to this study, this is however complicated by the presence of a high number of multiple HR-HPV genotypes associated with HIV infection and the limited knowledge of the contribution made by each genotype in the pathogenesis of ICC. Evidence regarding cross-protection of the vaccines is still scarce; therefore, the nonavalent vaccine may be the most effective option in our population given the high rate of multiple HPV infections (51%) noted, regardless of HIV status. Further studies, including cross-protection and cost-benefit ratios, will be required to determine the most advantageous type of HPV vaccination in the Zimbabwean setting.
We recognize several limitations to our study. There are no standardized laboratory protocols for HPV DNA extraction and amplification methods, and hence, it is difficult to compare results even those from the same population. Another limitation to the study was lack of data as to when participants acquired HIV. This prevents us from estimating the potential impact that the period of infection may have had on the distribution of HPV genotypes.
The current policy regarding HIV-positive women and cervical screening allows for annual Pap smears for these women, as they have higher risk of developing ICC. Current cervical cancer screening coverage of this target population is less than 10% 3 because of lack of facilities and human resources including cytopathologists and screeners. There should be shorter screening intervals to allow for the early detection of the lesions that are being detected relatively much earlier in HIV-positive women. Concomitant HR-HPV testing has been recommended, 30 but the high prevalence of HR-HPV makes this exercise costly and of possibly limited benefit in a resource-poor setting like Zimbabwe.
HIV and HPV have each been shown to facilitate infection with the other 29 ; given our findings therefore, it is recommended that programs aimed at controlling one infection should also target the other.
CONCLUSIONS
In conclusion, this study shows that among women with ICC, the proportion with multiple genotypes is high and almost equal in both HIV-positive and HIV-negative participants. This has important implications on the choice and anticipated benefits of each HPV vaccine as effective vaccines should be polyvalent and active against the most common oncogenic HPV genotypes in that geographic region. The nonavalent vaccine seems most ideal for our population, regardless of HIV status. HIV does seem to have an impact on the distribution of some HPV genotypes as shown by the significant difference in the prevalence of HPV 18 by HIV serostatus. Larger studies are needed to further investigate the effect and significance of HIV on other genotypes. Further studies are needed to understand the role of multiple HPV infections in the pathogenesis of ICC.
There is need for close monitoring of both HIV-related and HPV/CIN parameters before and during ART treatment as part of a comprehensive cervical cancer prevention program and vaccination programs. We should aim to vaccinate those HIV-positive and HIV-negative women who fall within the local age guidelines.
